Use of the ratio of ventricular enlargement for the treatment of Alzheimer's disease with intravenous immunoglobulin and Method for evaluating the therapeutic efficacy
Requirement 1: methods of treatment in patients with Alzheimer's disease, including (a) sequential steps to determine the volume of the patient's central ventricle through magnetic resonance imaging (IRM),Therefore, a reference value of ventricular volume was obtained； (b) a therapeutic agent to keep the brain was used for the treatment of Alzheimer's disease for the first time； (c) the ventricular volume of the brain was determined by IRM. Therefore, the first intermediate value of ventricular volume was obtained； (d) the intermediate value of stage (c) was compared with the reference value of stage (a)；(e) When level (d) indicates an increase from the reference value to the first intermediate value, and the increase is equal to or greater than the expected increase in ventricular volume of Alzheimer's patients, but without treatment, the use of brain preservation therapy agent with increased dose or frequency is increased Treatment of the disease within the same period as the first period,Or maintain the use of brain maintaining dose or frequency therapeutics when (d) indicates that there is no increase from the reference value to the first intermediate value, or that the increase is less than the increaseIt is expected to be within the ventricular volume of patients with Alzheimer's, but not treated for the same period of time as the first cycle.There, the therapeutic agent is a therapeutic agent that protects the brain through immunoglobulins. Claim 7: method of claim 1, wherein the therapeutic agent is immunoglobulin injection (lglv).Reivindicación 1: Un método para tratar la enfermedad de Alzheimer en un sujeto que lo necesite, que comprende las etapas secuenciales de: (a) determinar el volumen ventricular en el cerebro del sujeto mediante imágenes por resonancia magnética (IRM), obteniéndose así un valor de referencia del volumen ventricular； (b) la administración de un agente terapéutico para la preservación del cerebro al sujeto con el fin de tratar la enfe
